Jim Martineau

Person

Mentions

Episodes

Claims

Jim Martineau, mentioned 9 times across podcast episodes and expert conversations analyzed by Sonic.

What Jim Martineau has said

Gnosis Bio has demonstrated the ability to silence genes in the brain, heart, lung, muscle, kidney, and small intestine.

bullish·Jim Martineau

Gnosis Bio's platform is approximately 80% cheaper and three times faster for developing targeted gene silencing medicines compared to traditional methods.

bullish·Jim Martineau

Jim Martineau predicts that within five years, the term 'undruggable' will be eliminated from the pharmaceutical lexicon due to AI's ability to design molecules for any target.

bullish·Jim Martineau

Gnosis Bio has demonstrated the ability to silence genes in the brain, heart, lung, muscle, kidney, and small intestine.

Expert perspectiveJim MartineauApr 19

Gnosis Bio's platform is approximately 80% cheaper and three times faster for developing targeted gene silencing medicines compared to traditional methods.

Expert perspectiveJim MartineauApr 19

Jim Martineau predicts that within five years, the term 'undruggable' will be eliminated from the pharmaceutical lexicon due to AI's ability to design molecules for any target.

SpeculativeJim MartineauApr 19

Gnosis Bio has public collaborations with Johnson & Johnson, Daiichi Sankyo, and other top 10 global biopharma companies.

Expert perspectiveJim MartineauApr 19

Over the last five years, the success rate for building a drug delivery system at Gnosis Bio has improved from one in a trillion to a 10-30% success rate due to its AI platform.

Expert perspectiveJim MartineauApr 19

Gnosis Bio has raised more capital from pharmaceutical partnerships than from traditional venture capital investors.

Expert perspectiveJim MartineauApr 19

Existing gene silencing medicines on the market have a clinical trial success rate of approximately 70%, compared to a 95% failure rate for many traditional medicines.

Expert perspectiveJim MartineauApr 19

Avidity Bio was recently acquired for $12 billion for its technology that delivers gene silencing therapies to skeletal muscle.

Expert perspectiveJim MartineauApr 19

The FDA is working on creating safety-guaranteed models for certain classes of drugs like monoclonal antibodies, which could eliminate the need for some safety trials.

Expert perspectiveJim MartineauApr 19

Create a free account to see Jim Martineau's full intelligence report - every claim, the relationship network, and AI Q&A across all sources. No card needed.

Get started free

Back to Entities Entity Detail